Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Breast Cancer Prevention in BRCA1 Mutation Carriers
NCT04711109Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2023
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in breast cancer, sponsored by Cancer and Leukemia Group B. Started Feb 2023; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04711109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711109.